STOCK TITAN

Adaptive Biotechnologies SEC Filings

ADPT NASDAQ

Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Adaptive Biotechnologies Corporation filings document financial results, governance matters, registered common stock, and material events for a commercial-stage biotechnology issuer. Recent 8-K reports furnish quarterly and annual operating results, press releases, investor presentation materials, and disclosures tied to the company’s MRD business and immune medicine platform.

The company’s proxy materials cover board and shareholder voting matters, executive compensation, equity awards, and related governance disclosures. Other filings identify ADPT common stock listed on Nasdaq and disclose material agreement activity connected to research and development collaborations, including immune medicine and TCR-antigen programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags
current report
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

How many Adaptive Biotechnologies (ADPT) SEC filings are available on StockTitan?

StockTitan tracks 122 SEC filings for Adaptive Biotechnologies (ADPT), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Adaptive Biotechnologies (ADPT)?

The most recent SEC filing for Adaptive Biotechnologies (ADPT) was filed on August 5, 2025.